Sleep and antidepressant treatment
The aim of this review was to describe the sleep anomalies in depression, the effects of antidepressants on sleep, the usefulness of antidepressants in the treatment of primary insomnia and insomnia in other psychiatric disorders. Depression is associated with abnormalities in the sleep pattern that...
Saved in:
| Published in: | Current pharmaceutical design Vol. 18; no. 36; p. 5802 |
|---|---|
| Main Authors: | , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United Arab Emirates
01.12.2012
|
| Subjects: | |
| ISSN: | 1873-4286, 1873-4286 |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | The aim of this review was to describe the sleep anomalies in depression, the effects of antidepressants on sleep, the usefulness of antidepressants in the treatment of primary insomnia and insomnia in other psychiatric disorders. Depression is associated with abnormalities in the sleep pattern that include disturbances of sleep continuity, diminished slow-wave sleep (SWS) and altered rapid eye movement (REM) sleep parameters. Although none of the reported changes in sleep are specific to depression, many of them, for example increased REM density and reduced amount of SWS in the first sleep cycle, are used as biological markers for research on depression and in the development of antidepressant drugs. An antidepressant should reverse abnormalities in the sleep pattern. However, many antidepressants can worsen sleep. Because of the activating effects of some drugs, for example imipramine, desipramine, fluoxetine, paroxetine, venlafaxine, reboxetine and bupropion, many patients who take them have to be co-prescribed with sleep-promoting agents to improve sleep. Even in maintenance treatment with activating antidepressants as many as 30-40% of patients may still suffer from insomnia. Antidepressants with sleep-promoting effects include sedative antidepressants, for example doxepin, mirtazapine, trazodone, trimipramine, and agomelatine which promotes sleep not through a sedative action but through resynchronization of the circadian rhythm. Sedative antidepressants are frequently used in the treatment of primary insomnia, although not many double-blind studies have been provided to support such an approach to insomnia treatment. One exception is doxepin, which has been approved for the treatment of insomnia characterized by difficulties in maintaining sleep. |
|---|---|
| AbstractList | The aim of this review was to describe the sleep anomalies in depression, the effects of antidepressants on sleep, the usefulness of antidepressants in the treatment of primary insomnia and insomnia in other psychiatric disorders. Depression is associated with abnormalities in the sleep pattern that include disturbances of sleep continuity, diminished slow-wave sleep (SWS) and altered rapid eye movement (REM) sleep parameters. Although none of the reported changes in sleep are specific to depression, many of them, for example increased REM density and reduced amount of SWS in the first sleep cycle, are used as biological markers for research on depression and in the development of antidepressant drugs. An antidepressant should reverse abnormalities in the sleep pattern. However, many antidepressants can worsen sleep. Because of the activating effects of some drugs, for example imipramine, desipramine, fluoxetine, paroxetine, venlafaxine, reboxetine and bupropion, many patients who take them have to be co-prescribed with sleep-promoting agents to improve sleep. Even in maintenance treatment with activating antidepressants as many as 30-40% of patients may still suffer from insomnia. Antidepressants with sleep-promoting effects include sedative antidepressants, for example doxepin, mirtazapine, trazodone, trimipramine, and agomelatine which promotes sleep not through a sedative action but through resynchronization of the circadian rhythm. Sedative antidepressants are frequently used in the treatment of primary insomnia, although not many double-blind studies have been provided to support such an approach to insomnia treatment. One exception is doxepin, which has been approved for the treatment of insomnia characterized by difficulties in maintaining sleep. The aim of this review was to describe the sleep anomalies in depression, the effects of antidepressants on sleep, the usefulness of antidepressants in the treatment of primary insomnia and insomnia in other psychiatric disorders. Depression is associated with abnormalities in the sleep pattern that include disturbances of sleep continuity, diminished slow-wave sleep (SWS) and altered rapid eye movement (REM) sleep parameters. Although none of the reported changes in sleep are specific to depression, many of them, for example increased REM density and reduced amount of SWS in the first sleep cycle, are used as biological markers for research on depression and in the development of antidepressant drugs. An antidepressant should reverse abnormalities in the sleep pattern. However, many antidepressants can worsen sleep. Because of the activating effects of some drugs, for example imipramine, desipramine, fluoxetine, paroxetine, venlafaxine, reboxetine and bupropion, many patients who take them have to be co-prescribed with sleep-promoting agents to improve sleep. Even in maintenance treatment with activating antidepressants as many as 30-40% of patients may still suffer from insomnia. Antidepressants with sleep-promoting effects include sedative antidepressants, for example doxepin, mirtazapine, trazodone, trimipramine, and agomelatine which promotes sleep not through a sedative action but through resynchronization of the circadian rhythm. Sedative antidepressants are frequently used in the treatment of primary insomnia, although not many double-blind studies have been provided to support such an approach to insomnia treatment. One exception is doxepin, which has been approved for the treatment of insomnia characterized by difficulties in maintaining sleep.The aim of this review was to describe the sleep anomalies in depression, the effects of antidepressants on sleep, the usefulness of antidepressants in the treatment of primary insomnia and insomnia in other psychiatric disorders. Depression is associated with abnormalities in the sleep pattern that include disturbances of sleep continuity, diminished slow-wave sleep (SWS) and altered rapid eye movement (REM) sleep parameters. Although none of the reported changes in sleep are specific to depression, many of them, for example increased REM density and reduced amount of SWS in the first sleep cycle, are used as biological markers for research on depression and in the development of antidepressant drugs. An antidepressant should reverse abnormalities in the sleep pattern. However, many antidepressants can worsen sleep. Because of the activating effects of some drugs, for example imipramine, desipramine, fluoxetine, paroxetine, venlafaxine, reboxetine and bupropion, many patients who take them have to be co-prescribed with sleep-promoting agents to improve sleep. Even in maintenance treatment with activating antidepressants as many as 30-40% of patients may still suffer from insomnia. Antidepressants with sleep-promoting effects include sedative antidepressants, for example doxepin, mirtazapine, trazodone, trimipramine, and agomelatine which promotes sleep not through a sedative action but through resynchronization of the circadian rhythm. Sedative antidepressants are frequently used in the treatment of primary insomnia, although not many double-blind studies have been provided to support such an approach to insomnia treatment. One exception is doxepin, which has been approved for the treatment of insomnia characterized by difficulties in maintaining sleep. |
| Author | Wichniak, Adam Wierzbicka, Aleksandra Jernajczyk, Wojciech |
| Author_xml | – sequence: 1 givenname: Adam surname: Wichniak fullname: Wichniak, Adam email: wichniak@ipin.edu.pl organization: Third Department of Psychiatry, Institute of Psychiatry and Neurology, Warsaw, Poland. wichniak@ipin.edu.pl – sequence: 2 givenname: Aleksandra surname: Wierzbicka fullname: Wierzbicka, Aleksandra – sequence: 3 givenname: Wojciech surname: Jernajczyk fullname: Jernajczyk, Wojciech |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22681161$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNj0tLxEAQhAdZcR_6BzzI4slLdLp7knSOsviCBQ_qOczsdCCSl5nJwX9vwBU8FFWHrwpqrRZd34lSl6BvEXJzB8SQAQKyphQp03yiVsA5JQY5W_zLS7UO4VNrwALMmVoiZgxzd6Wu3xqRYWs7PyvWXoZRQpjjNo5iYytdPFenlW2CXBx9oz4eH953z8n-9elld79PnMkwJmgci7G5O5B3RK6wriIsiIucjYXKUlVZSLVmj5QWBNo7awiNeON06nCjbn53h7H_miTEsq3DQZrGdtJPoQTMCaFA5hm9OqKTa8WXw1i3dvwu_37hDzznT-k |
| CitedBy_id | crossref_primary_10_1016_j_sleep_2021_10_013 crossref_primary_10_1016_j_jad_2017_09_032 crossref_primary_10_1177_03000605241290715 crossref_primary_10_1038_s43856_021_00046_8 crossref_primary_10_1016_j_rmr_2017_04_005 crossref_primary_10_1177_0269881119874485 crossref_primary_10_1111_jsr_13891 crossref_primary_10_1016_j_jad_2023_10_103 crossref_primary_10_3390_jcm9092862 crossref_primary_10_1007_s00216_015_8660_z crossref_primary_10_1016_j_smrv_2020_101357 crossref_primary_10_1016_j_jad_2022_11_062 crossref_primary_10_1016_j_jad_2024_06_005 crossref_primary_10_1016_j_jpsychores_2024_111996 crossref_primary_10_1089_cap_2015_0260 crossref_primary_10_1007_s11920_017_0816_4 crossref_primary_10_1134_S0022093024030293 crossref_primary_10_1159_000439384 crossref_primary_10_12688_f1000research_7694_2 crossref_primary_10_12688_f1000research_7694_1 crossref_primary_10_1016_j_biopsych_2025_07_023 crossref_primary_10_3109_07420528_2015_1077855 crossref_primary_10_3390_brainsci15090983 crossref_primary_10_36290_med_2025_017 crossref_primary_10_1097_GME_0000000000000311 crossref_primary_10_1007_s41105_021_00315_y crossref_primary_10_1007_s00228_013_1567_8 crossref_primary_10_36290_psy_2022_030 crossref_primary_10_1111_sbr_12092 crossref_primary_10_17311_sciintl_2025_35_45 crossref_primary_10_1016_j_molliq_2016_07_125 crossref_primary_10_1111_acps_12523 crossref_primary_10_1016_j_jsmc_2020_02_004 crossref_primary_10_1097_GME_0000000000001647 crossref_primary_10_1016_j_jamda_2012_09_002 crossref_primary_10_1016_j_jsmc_2017_03_006 crossref_primary_10_1016_j_neuropharm_2014_04_017 crossref_primary_10_1016_j_psychres_2016_10_064 crossref_primary_10_33450_fpn_2019_01_003 crossref_primary_10_1097_GME_0000000000002386 crossref_primary_10_1177_0269881115592347 crossref_primary_10_1002_brb3_70446 crossref_primary_10_1080_14656566_2019_1674283 crossref_primary_10_1002_jsf2_70004 crossref_primary_10_1016_j_neulet_2024_138007 crossref_primary_10_3389_fpsyt_2023_1122344 crossref_primary_10_1007_s40122_017_0089_y crossref_primary_10_1038_s41386_025_02066_7 crossref_primary_10_1016_j_psychres_2020_113239 crossref_primary_10_3390_ijerph17218092 crossref_primary_10_1016_j_psychres_2024_115811 crossref_primary_10_1017_neu_2014_30 crossref_primary_10_1016_j_psc_2015_07_010 crossref_primary_10_1038_s41467_023_41249_y crossref_primary_10_4103_indianjpsychiatry_indianjpsychiatry_207_23 crossref_primary_10_12688_f1000research_24386_1 crossref_primary_10_15446_rcciquifa_v50n3_100239 crossref_primary_10_1007_s41105_021_00311_2 crossref_primary_10_1080_15402002_2016_1266491 crossref_primary_10_1016_j_jpsychires_2017_10_013 crossref_primary_10_1016_j_psc_2016_04_002 crossref_primary_10_3389_fneur_2025_1543725 crossref_primary_10_1111_jcpp_12812 crossref_primary_10_1016_j_hermed_2024_100893 crossref_primary_10_1097_PRA_0000000000000462 crossref_primary_10_2147_NDT_S257723 crossref_primary_10_1177_2049463714525355 crossref_primary_10_1016_j_smrv_2018_01_008 crossref_primary_10_3109_09540261_2013_812067 crossref_primary_10_1097_MD_0000000000012383 crossref_primary_10_3390_medsci6040095 crossref_primary_10_1080_20008198_2020_1740492 crossref_primary_10_1016_j_genhosppsych_2020_08_004 crossref_primary_10_1080_14737175_2023_2267761 crossref_primary_10_1186_s12991_022_00390_6 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.2174/138161212803523608 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1873-4286 |
| ExternalDocumentID | 22681161 |
| Genre | Journal Article Review |
| GroupedDBID | --- .5. 0R~ 29F 36B 4.4 53G 5GY 69Q 7X7 88E 8AO 8FI 8FJ 8R4 8R5 AAEGP ABEEF ABJNI ABMOS ABUWG ABVDF ACGFO ACGFS ACITR ACIWK ACPRK ACZAY ADBBV AENEX AFKRA AFRAH AFUQM AGJNZ AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS ANTIV BENPR BPHCQ BVXVI C1A CCPQU CGR CS3 CUY CVF DU5 EBS ECM EIF EJD F5P FYUFA GH2 HMCUK HZ~ IPNFZ KCGFV KFI M1P NPM O9- P2P PHGZT PQQKQ PROAC PSQYO Q2X RIG UKHRP 7X8 AFHZU |
| ID | FETCH-LOGICAL-b462t-24b8e4a7bc3db33b9abf329389784a1fa3ffa15008d2359310dba4324ed4b05b2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 91 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000309981200003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1873-4286 |
| IngestDate | Thu Oct 02 06:46:26 EDT 2025 Thu Apr 03 07:04:41 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 36 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-b462t-24b8e4a7bc3db33b9abf329389784a1fa3ffa15008d2359310dba4324ed4b05b2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| PMID | 22681161 |
| PQID | 1273219288 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1273219288 pubmed_primary_22681161 |
| PublicationCentury | 2000 |
| PublicationDate | 2012-12-01 |
| PublicationDateYYYYMMDD | 2012-12-01 |
| PublicationDate_xml | – month: 12 year: 2012 text: 2012-12-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United Arab Emirates |
| PublicationPlace_xml | – name: United Arab Emirates |
| PublicationTitle | Current pharmaceutical design |
| PublicationTitleAlternate | Curr Pharm Des |
| PublicationYear | 2012 |
| SSID | ssj0012914 |
| Score | 2.3749425 |
| SecondaryResourceType | review_article |
| Snippet | The aim of this review was to describe the sleep anomalies in depression, the effects of antidepressants on sleep, the usefulness of antidepressants in the... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 5802 |
| SubjectTerms | Antidepressive Agents - adverse effects Antidepressive Agents - therapeutic use Depression - complications Depression - drug therapy Depression - physiopathology Depression - psychology Humans Hypnotics and Sedatives - adverse effects Hypnotics and Sedatives - therapeutic use Risk Factors Sleep - drug effects Sleep Initiation and Maintenance Disorders - drug therapy Sleep Initiation and Maintenance Disorders - etiology Sleep Initiation and Maintenance Disorders - physiopathology Sleep Wake Disorders - drug therapy Sleep Wake Disorders - etiology Sleep Wake Disorders - physiopathology Sleep Wake Disorders - psychology Treatment Outcome |
| Title | Sleep and antidepressant treatment |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/22681161 https://www.proquest.com/docview/1273219288 |
| Volume | 18 |
| WOSCitedRecordID | wos000309981200003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8QwEB7U9eDF92N9UUX2tMEm6SM9iYiLB10KrrK3kjQJLEh3tauw_95J27UnQfDQ0EuhTCYz32RmvgG4wqABowBuiWuzJIEONUnQ8RCVx0nMLZWmohR6fYyHQzEeJ2lz4VY2ZZVLm1gZaj3N3R35NUU_i6eLCXEzeyduapTLrjYjNFahwxHKuJKueNxmEVhScXtTEXOCMDuqm2YcCL-mLmFG0W4LRwjKI1_8DjErVzPY-u9PbsNmAzK921ordmDFFLvQS2uW6kXfG7VNV2Xf63lpy1-92IPL5zdjZp4sND7zSVMri6_eT1X6PrwM7kd3D6QZpUBUELE5YYESJpCxyrlWnKtEKsvR0wsMIgNJreTWSsSGvtCMhwliPq2kI-szOlB-qNgBrBXTwhyBx0PfyiBhucTQjUa-5IqryBjOtAgjEXXhYimbDFXV5R9kYaafZdZKpwuHtYCzWc2pkSEKFBR35PgPX5_ABsIWVheVnELH4kE1Z7Cef80n5cd5pQO4DtOnbx5juOA |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Sleep+and+antidepressant+treatment&rft.jtitle=Current+pharmaceutical+design&rft.au=Wichniak%2C+Adam&rft.au=Wierzbicka%2C+Aleksandra&rft.au=Jernajczyk%2C+Wojciech&rft.date=2012-12-01&rft.eissn=1873-4286&rft.volume=18&rft.issue=36&rft.spage=5802&rft_id=info:doi/10.2174%2F138161212803523608&rft_id=info%3Apmid%2F22681161&rft_id=info%3Apmid%2F22681161&rft.externalDocID=22681161 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1873-4286&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1873-4286&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1873-4286&client=summon |